{"id":740081,"date":"2023-03-14T16:44:28","date_gmt":"2023-03-14T20:44:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/"},"modified":"2023-03-14T16:44:28","modified_gmt":"2023-03-14T20:44:28","slug":"sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/","title":{"rendered":"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023"},"content":{"rendered":"
\n

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-103, a conditionally active, monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, FL.<\/p>\n

\n Presentation Details:<\/strong>\n <\/p>\n

\n Title: <\/strong>Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironment
Presentation Type:<\/strong> Poster
Session Category:\u00a0<\/strong>Tumor Biology
Session Title:\u00a0<\/strong>Inflammation and Tumor Progression
Date and time:<\/strong> Tuesday, April 18, 2023 1:30 PM – 5:00 p.m. ET
Location:\u00a0<\/strong>Poster Section 5<\/p>\n

The abstract will be available online on the AACR Online Program Planner<\/u><\/a>. The poster will be made available on the Sensei Bio website following the presentation.<\/p>\n

\n About Sensei Biotherapeutics<\/strong>
\n
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb\u2122 (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei\u2019s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit\u00a0www.senseibio.com<\/a>, and follow the company on Twitter @SenseiBio and\u00a0LinkedIn<\/a>.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>
\n
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as \u201cbelieve\u201d, \u201cdesigned to,\u201d \u201cexpect\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cwill\u201d, and similar expressions, and are based on Sensei\u2019s current beliefs and expectations. These forward-looking statements include expectations regarding the development of Sensei\u2019s product candidates and platforms; the potential safety profile of Sensei\u2019s product candidates; the potential benefits of Sensei\u2019s product candidates; and the expected release of new preclinical data for SNS-103. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei\u2019s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei\u2019s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei\u2019s product candidates; the risk that Sensei\u2019s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate; risks associated with Sensei\u2019s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which Sensei may not always have full control; risks regarding the accuracy of Sensei\u2019s estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei\u2019s Annual Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 8, 2022 and Sensei\u2019s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. <\/p>\n

Investor Contact:<\/strong>
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com<\/a>\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-103, a conditionally active, monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, FL. Presentation Details: Title: Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironmentPresentation Type: PosterSession Category:\u00a0Tumor BiologySession Title:\u00a0Inflammation and Tumor ProgressionDate and time: Tuesday, April 18, 2023 1:30 PM – 5:00 p.m. ETLocation:\u00a0Poster Section 5 The abstract will be available online on the AACR Online Program Planner. The … <\/p>\n

Continue reading “Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740081","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-103, a conditionally active, monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, FL. Presentation Details: Title: Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironmentPresentation Type: PosterSession Category:\u00a0Tumor BiologySession Title:\u00a0Inflammation and Tumor ProgressionDate and time: Tuesday, April 18, 2023 1:30 PM – 5:00 p.m. ETLocation:\u00a0Poster Section 5 The abstract will be available online on the AACR Online Program Planner. The … Continue reading "Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T20:44:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023\",\"datePublished\":\"2023-03-14T20:44:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/\"},\"wordCount\":720,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/\",\"name\":\"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc=\",\"datePublished\":\"2023-03-14T20:44:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/","og_locale":"en_US","og_type":"article","og_title":"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Market Newsdesk","og_description":"BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-103, a conditionally active, monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, FL. Presentation Details: Title: Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironmentPresentation Type: PosterSession Category:\u00a0Tumor BiologySession Title:\u00a0Inflammation and Tumor ProgressionDate and time: Tuesday, April 18, 2023 1:30 PM – 5:00 p.m. ETLocation:\u00a0Poster Section 5 The abstract will be available online on the AACR Online Program Planner. The … Continue reading \"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-14T20:44:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023","datePublished":"2023-03-14T20:44:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/"},"wordCount":720,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/","name":"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc=","datePublished":"2023-03-14T20:44:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4Nzk5NiM1NDU4OTUyIzIyMDQ0Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-present-new-preclinical-data-for-sns-103-a-conditionally-active-monoclonal-antibody-targeting-entpdase1-cd39-at-the-american-association-for-cancer-research-aacr-annual\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740081"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740081\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}